ABSTRACT
INTRODUCTION 43
Hypertension is a leading cause of morbidity and mortality worldwide (24) . Approximately 80 44 million people, age >20 years, in the United States have high blood pressure (>140/90 mmHg) (33). 45
Hypertension is a major risk factor of cardiovascular disease (43), stroke (21), and chronic kidney disease 46 (CKD) (14,18) . Chronic elevation of arterial pressure leads to reduced glomerular filtration rate (GFR), 47 albuminuria, and eventually renal failure (40) . sensitive hypertension in Dahl salt-sensitive (SS) rats (9, 10) . Experiments have demonstrated that an 55 elevated sodium chloride intake in SS rats is associated with increased T-lymphocytes and 56 macrophages in the renal interstitium, a progressive elevation of arterial blood pressure, albuminuria, 57 and renal histological damage (9, 10) . These phenotypes are remarkably similar to those observed in 58 patients (1, 13) . Subsequent experiments in the Dahl SS have demonstrated that pharmacological 59 treatments or genetic manipulations that inhibit the immune system result in an attenuation of salt-60 sensitive hypertension. These data demonstrate that the immune system amplifies salt-sensitive 61 hypertension and kidney damage in SS rats. 62
Numerous experiments have assessed the mechanisms by which immune cells may influence 63 kidney disease and hypertension. It is know that immune cells in the kidney release a number of 64 different cytokines, and the accumulation and action of these inflammatory molecules in target 65 organs have been implicated in the exacerbation of hypertensive pathology (11,32) . Several 66 inflammatory cytokines, including TNF-α (12), IL-17 (26), IFN-γ (39), and IL-6 (7,22) have been shown 67 to play a role in the development of hypertension. Previous data from our laboratory showed that T-68 lymphocytes isolated from the damaged kidneys of Dahl SS rats fed high salt expressed significantly 69 greater mRNA of cytokines and other inflammatory molecules when compared to circulating T-70 lymphocytes (37). Notably, interleukin-6 mRNA expression was 54-fold higher in T cells in the kidney 71 compared to circulating T-cells. These studies indicate a possible role of IL-6 in the development of 72 salt-sensitive hypertension. 73 IL-6 is a pro-inflammatory cytokine produced by various cells including macrophages, T-74 lymphocytes, endothelial cells, and vascular smooth muscle cells (16). It plays a critical role in driving 75 the inflammatory process in various autoimmune diseases such as rheumatoid arthritis and multiple 76 sclerosis (34,36). IL-6 has been implicated as causative in models of experimental hypertension 77 including angiotensin II (Ang II) (22) and cold-induced (7) hypertension. Human data showed that IL-6 78 is an independent risk factor for hypertension in otherwise healthy human subjects (4), and that 79 serum IL-6 concentration is significantly higher in hypertensive patients compared to normotensive 80 patients (6) . Experimental studies have demonstrated that IL-6 -/-mice have attenuated hypertension 81 and albuminuria when exposed to Ang II infusion and high salt, further supporting a possible role for 82 IL-6 in the development of hypertension (5,22). Additionally IL-6 mRNA expression is increased in 83 kidney biopsies of CKD patients compared to a normal control group, and is even further elevated in 84 biopsies of CKD patients with hypertension (46) . IL-6 mRNA expression was also found to be 85 significantly elevated in the kidneys of mice after 2 weeks of Ang II infusion compared to saline-86 infused mice (46) . These findings, along with our previous observation that infiltrating renal T cells in 87 the Dahl SS kidney significantly up-regulate IL-6 (37), suggest that IL-6 may exacerbate Dahl SS 88 pathology. The current studies were therefore performed to test the hypothesis that IL-6 mediates 89 salt-sensitive hypertension and renal damage in Dahl SS rats. 90
91

METHODS 92
Study Animals: Studies were performed on male SS/JrHsdMcwi (Dahl SS) rats obtained from a 93 colony at the Medical College of Wisconsin. Study animals were fed purified AIN-76A rodent diet (Dyets,  94 Inc, Bethlehem, PA) containing 0.4% NaCl from weaning. Starting at nine weeks of age, the salt content 95 of the diet was increased to 4.0% NaCl. The Institutional Animal Care and Use Committee of the Medical 96
College of Wisconsin approved all studies. 97
Study Protocol: Experiments were performed on 57 rats; for technical and logistical reasons, all 98 measurements were not made on every animal. At 9 weeks of age, the dietary salt content was 99 increased from a low (0.4% NaCl) to a high salt diet (4.0% NaCl). Animals were randomized into two 100 groups to receive a daily intraperitoneal injection of either vehicle (normal goat IgG; 4 µg /day in PBS) or 101 goat anti-rat IL-6 neutralizing antibody (anti-rat IL-6; 4 µg /day, R&D Systems, Minneapolis, MN) during 102 the 11 day period of high salt intake (N = 13-16/group). In the interventional experiments, lyophilized 103 anti-rat IL-6 antibody and goat IgG were diluted in sterile phosphate-buffered saline (PBS), according to 104 pressure was continuously monitored for five days while the rats were maintained on the low salt (0.4% 114 NaCl) diet and for eleven days following the transition to the high salt (4.0% NaCl) diet. Overnight urine 115 collections were obtained in metabolic cages while on low salt diet and on days 7 and 11 of the high salt 116 diet. Urine studies were performed to assess urinary creatinine, albumin, and protein excretion rates as 117 well as urinary sodium and potassium excretion rates. After eleven days of high salt intake, the rats were 118 deeply anesthetized and the kidneys were flushed with heparinized saline and removed for histology, 119
ELISA and immune cell isolation. A final arterial blood sample was also obtained for serum creatinine 120 and electrolyte analysis. 121
Histological Analysis of Kidney Tissues: Kidneys (n=6 per group) were obtained for histological 122 analysis from rats maintained on the high salt diet and treated with vehicle or anti-rat IL-6 antibody as 123 described above. The rats were deeply anesthetized with sodium pentobarbital (83 mg/kg, i.p.); the 124 kidneys were flushed with heparinized saline and then removed, de-capsulated, weighed and placed in 125 10% formaldehyde. The tissue was paraffin embedded and stained with Masson's trichrome. Slides were 126 photographed using a Nikon E-400 fitted with a Spot Insight camera; digital micrographs were taken at 127 different magnifications. Individual glomeruli (40 per rat) were evaluated using the semi quantitative 128 index method and scored from 0 (best) to 4 (worst) on the basis of glomerulosclerosis and mesangial 129 expansion as we described previously (27,28,30). The percentage of the outer medullary tissue 130 containing blocked tubules filled with protein casts was quantified by determining the proportion of red-131 stained structures in this region using Metamorph Image Analysis software (version 4.6, Universal 132
Imaging Systems Corp) as we described previously (27,28,30). The grading of glomerular and medullary 133 damage was performed in a blinded manner. 134
Immunohistochemistry was performed to localize ED1 in the kidneys of Dahl SS/Mcw rats fed 135 the 4.0% NaCl diet as we previously described (27). Briefly, excised kidneys were fixed in 10% 136 formaldehyde, paraffin embedded, cut in 3 µm sections, and mounted as described above. Sections 137 were then deparaffinized with xylene and ethanol, and incubated with Proteinase K for antigen retrieval. 138
Endogenous biotin and peroxidase activity were blocked by incubation with avidin and biotin, and 139 hydrogen peroxide, respectively. The primary ED1 monoclonal antibody (MCA341R; Serotec Inc.) was 140 used at a dilution of 1:400 and incubated at room temperature for 60 minutes. A biotinylated horse anti-141 mouse secondary antibody was used for development with avidin-biotinylated horseradish peroxidase 142 complex (Vectastain ABC kits; Vector Laboratory, Burlingame, CA) and 0.02% H2O2 + 0.1% 143 diaminobenzidine tetrahydrochloride (DAB). The slides were lightly counterstained with aniline blue dye 144 to assist in tissue visualization and determination if tissue damage and macrophage infiltration were co-145
localized. 146
Quantification of IL-6: An ELISA (Thermo Scientific, Pierce Biotechnology, Rockford, IL) was 147 performed to assess IL-6 levels in the kidney tissue of Dahl SS rats maintained on the high-salt diet and 148 treated with vehicle or anti-IL-6 as described above. The rats were euthanized with an overdose of 149 sodium pentobarbital (50 mg/kg i.p.), and the kidneys were flushed with heparinized saline and 150 removed, de-capsulated and separated into cortical and medullary sections, and frozen on dry ice. 151
Isolated tissue was stored at −80°C un l protein extrac on. Total protein from kidneys was extracted 152 using RIPA buffer (Thermo Scientific). Briefly, 20 mg of flash-frozen tissue was added to 1 ml of RIPA 153 buffer; tissue was homogenized using a mortar and pestle; the homogenized solution was then 154 incubated at 4 ᴼC for 2 hours on a rocker platform. The sample was then centrifuged at 12000 RPM for 155 20 min to pellet debris. The supernatant containing total protein was transferred to a new tube. The 156 protein concentration was determined using DC Protein Assay (Bio-Rad) with albumin as a standard. 157
Immune Cell Isolation and Flow Cytometry: A separate group of male rats were treated with 158
anti-IL-6 antibody or control IgG for 11 days, starting at 9 weeks of age, while maintained on 4% NaCl 159 diet. After 11 days of high salt intake, animals were anesthetized with sodium pentobarbital (50 mg/kg, 160 i.p.) and immune cells were isolated from the kidney as previously described (37,38 Body weight and other parameters are summarized in Table 1 . Body weight was not different 212 between the vehicle and anti-IL-6-treated groups, nor was total kidney weight. Urinary sodium and 213 potassium excretion rates on the low salt diet and after 11 days of high salt intake were also not 214 different between the groups. The similar body weight and steady-state sodium and potassium 215 excretion rates indicated equivalent food consumption in the groups. Conscious creatinine clearance, 216 measured at the conclusion of experiment, was also comparable between the vehicle and anti-IL-6-217 treated groups. 218
Representative histological images of kidneys obtained from the vehicle and anti-IL-6-treated 219 rats after 11 days on the 4% NaCl diet are illustrated in The present data, which demonstrate that Il-6 inhibition reduces immune cells in the kidney as well as 247 hypertension and the renal damage phenotype, indicate that IL-6 may function as a chemoattractant or 248 proliferating agent in the kidney. This concept is consistent with previous studies demonstrating that IL-249 6 is essential for macrophage migration in a mouse model of muscle injury (45). Although T lymphocytes 250 have been implicated (1, 9) in salt-sensitive hypertension, the mechanisms whereby T cells and other 251 immune cells exert their detrimental effects is still under investigation. A previous study from our 252 laboratory showed that the T lymphocytes in the kidney are activated and express several cytokines, 253 especially IL-6, in much greater abundance compared to peripheral T lymphocytes (37). This current 254 study provides insight into the potential role of IL-6 in the development of salt-sensitive hypertension. 255
Since IL-6 is known to be a pro-inflammatory cytokine that is released from various cell types, 256 including endothelial cells, vascular smooth muscle cells, lymphocytes, and macrophages (16), it is 257 possible that inhibition of IL-6 attenuated salt-sensitive hypertension and renal damage through a 258 variety of different mechanisms. IL-6 has been shown to be an independent risk factor for hypertension 259 in other wise heathy human subjects (4). Serum IL-6 level is significantly higher in hypertensive patients 260 compared to normotensive patients (6) . Additionally IL-6 expression levels are increased in kidney 261 biopsies of chronic kidney disease (CKD) patients compared to controls and further elevated in CKD 262 patients with hypertension (46) . 263
Angiotensin II and salt-mediated hypertension and kidney damage are attenuated in IL-6 knock-264 out mice, but the deleterious mechanisms of action are not clear (22). Interestingly, the same group of 265 investigators demonstrated that IL-6 is not required for mineralocorticoid-dependent hypertension in 266 mice (44), which is contrary to human data that showed that Ang II induces serum IL-6 in humans 267 through a mineralocorticoid receptor dependent mechanism (25). Previous attempts to explore the 268 mechanisms of IL-6 in hypertension have indicated that IL-6 does not affect Ang II-induced renal 269 vasoconstriction and there are likely other mechanisms causing attenuation of hypertension in IL-6 270 knock out mice (5). Others have postulated that IL-6 impairs pressure natriuresis (23), and it was shown 271 that genetic or pharmacological inhibition of IL-6 reduces hypertension and renal impairment and 272 fibrosis in Ang II-infused mice. In those studies, it was postulated that IL-6 mediates these effects by 273 inducing pro-fibrotic genes and increasing production of endothein-1 (ET 1) mRNA (46) . The effect of IL-274 6 inhibition on immune cell infiltration or proliferation has not been studied in hypertension models but 275 our data are in agreement with the effects for IL-6 on tissue macrophages in different disease models 276 (45). Though the present studies indicate a role of IL-6 to promote tissue macrophages, further studies 277 will be necessary to determine the major site of production of IL-6 within the body and determine the 278 mechanisms of action in hypertension and renal disease. Moreover, the potential interplay of IL-6 with 279 other cytokines to mediate hypertension and renal damage require further examination. 
